Whatcom County Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
(NQ: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News
Blog posts about
 
< Previous 1 2 3 4 5 6 7 8 Next >
Amylin Pharmaceuticals Inc. Draws Put Buying Attention Following Earnings Repot
April 19, 2010
Shares of Amylin Pharmaceuticals Inc. (AMLN) have retreated nearly 1% in the wake of the company's first-quarter earnings report...( Read More ) Read More
category AMLN
from SchaeffersResearch.com Trading Floor Blog
Charts of the Day - Harry Boxer, TheTechTrader.com
April 09, 2010
Today we’re going to go over some of the stocks on the long side that are looking pretty good. Las Vegas Sands Corp. (LVS) was a part of a very strong casino group today jumping a 1.30 or 5.67% on 63.8... Read More
from Charts of the Day by Harry Boxer
The stock looks set to continue its steep rally during the near term
April 01, 2010
This week, we had the distinct pleasure of selecting a bullish contrarian option trade for our good friends over at SFO Magazine...( Read More ) Read More
category AMLN
from SchaeffersResearch.com Market Observations
(NVO) Novo Nordisk’s Victoza Proves More Effective
March 31, 2010
category AMLN , Glaxosmithkline plc , Drug Manufacturers / Other , and 7 more.
from Stock Blog Hub
(VVUS) VIVUS Obesity Drug Application for Qnexa to Get FDA Review
March 29, 2010
category AMLN , Crane Company , Orexigen Therapeutics , and 8 more.
from Stock Blog Hub
FDA To Review VIVUS Drug
March 29, 2010
Recently, VIVUS, Inc. (NASDAQ:VVUS) announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the... Read More
category AMLN , External Research , Contributor , and 6 more.
from DailyMarkets.com
(ALKS) Alkermes Drug Pipeline Advances
March 19, 2010
Recently, Alkermes Inc. (ALKS) initiated a multidose early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist, which has the potential to... Read More
category AMLN , ALKS , LLY , and 5 more.
from Stock Blog Hub
(AMLN) Amylin Pharmaceuticals’ Drug Approval Delayed
March 16, 2010
The US Food and Drug Administration (FDA) recently issued a complete response letter delaying the approval of Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Co. (LLY) and Alkermes, Inc.’s (ALKS)... Read More
category AMLN , Glaxosmithkline plc , Biotechnology , and 9 more.
from Stock Blog Hub
Stocks Advancing Amid Heavy Short Interest - Amylin Pharmaceuticals Inc, Alkermes Inc, Cypress Bioscience Inc, Cell Therapeutics Inc
March 16, 2010
As explained in our education section, short interest is a useful sentiment indicator that measures the level of investor pessimism toward a stock...( Read More ) Read More
category AMLN
from SchaeffersResearch.com Trading Floor Blog
Mixed Close to Start Off the Week
March 15, 2010
The stock market indices ended mixed today, but started out very differently. They gapped lower, snapped back, couldn’t get through Friday’s late highs, and then rolled over in a sharp 3-wave decline,... Read More
from Harry's Hotline by Harry Boxer
Top 19 Gainers : 15th March 2010
March 15, 2010
from Small Cap Bear...
Regulatory Catalyst News: $ALKS, $AMLN, $LLY, $MNKD, $SVNT (AMLN, rated BUY)
March 15, 2010
Shares of Amylin Pharma (NASDAQ: AMLN) are rising by about 10% during early trading today on the issuance of a Complete Response Letter (CRL) from FDA for its once-weekly formulation of its diabetes... Read More
category Healthcare , Biotechnology & Drugs
from SocialPicks.com: Front Page Picks
Weekend Wrap-Up, Still Trying to Get Bullish
March 14, 2010
I’m having writer’s block this weekend .  Usually when I can’t think of what to write it helps me to go over our portfolios so I started this morning reviewing the Buy List but I didn’t get far because... Read More
category SONC , T , TXN , and 32 more.
from Phil’s Stock World
Bank Gains in This Sector Every Month
March 13, 2010
Wealth Daily Editor Ian Cooper explores the FDA decision trading strategy and offers several ways to trade it this month. Read More
from Wealth Daily
Analyst Upgrades and Downgrades BMY, SCCO, SAAS, KMT, HAL, LULU, PCYC, SGI, BTE, ULTI, LMNX, MJN, MWA, EDU, DNDN…
March 12, 2010
Aeropostale (ARO, News, Press Releases: 27.05 0.00 0.00%, yield: N/A, cap: 2.681B, 1yr target: 29.60) upgraded to Neutral from Underweight, $31 target, at Piper Jaffray Amylin Pharma (AMLN, News, Press... Read More
category InContact , HAL , Upgrades/Downgrades , and 37 more.
from CEOWORLD Magazine
Charts of the Day - Harry Boxer, TheTechTrader.com
March 11, 2010
Today I’m going to continue covering stocks that seem to be making some significant moves right now. OmniVision Technologies (OVTI), an old favorite of ours, had a big run from December through... Read More
from Charts of the Day by Harry Boxer
Analyst Upgrades and Downgrades DIS, KO, BA, BBT, FDX, RCL, CBEY, DFG, FITB, MTB, MSG, SBX…
March 04, 2010
Anadarko Petroleum (APC, news: 70.67 +0.50 +0.71%, cap: 34.809B, 1yr target: 81.64) reiterated Outperform, price target raised to $90 from $75, at FBR… BB&T (BBT, news: 27.975 +0.595 +2.17%, cap:... Read More
category BIG , FITB , DL , and 54 more.
from CEOWORLD Magazine
Charts of the Day - Harry Boxer, TheTechTrader.com
March 03, 2010
A new stock we initiated today, China Wind Systems (CWS), broke out of a wedge pattern at the apex of a coil at the 5.32 area, popped, took out the mid-February high, jumped 60 cents at one point and... Read More
from Charts of the Day by Harry Boxer
(ALKS) Alkermes Drug Application Gets New Target Date
March 01, 2010
Recently, the U.S. Food and Drug Administration (FDA) announced that inclement weather has forced the agency to delay the review of the new drug application (NDA) of the type II diabetes candidate,... Read More
category AMLN , JNJ , ALKS , and 7 more.
from Stock Blog Hub
(AMLN) Amylin Pharmaceuticals’ Obesity Drug Pipeline Advances
February 25, 2010
Amylin Pharmaceuticals, Inc. (AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin... Read More
category BMI , AMLN , Badger Meter Inc , and 9 more.
from Stock Blog Hub
AMLN’s Obesity Pipeline Advances
February 24, 2010
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and... Read More
category AMLN , External Research , Contributor , and 6 more.
from DailyMarkets.com
Traders Favor Calls on Amylin Pharmaceuticals Amid Lingering Pessimism
February 23, 2010
Amylin Pharmaceuticals (AMLN) has seen a surge in call trading today, as more than 14,700 contracts have changed hands...( Read More ) Read More
category AMLN
from SchaeffersResearch.com Trading Floor Blog
(ALKS) Alkermes Pipeline Announces Good News
February 17, 2010
Recently, Alkermes Inc. (ALKS) announced encouraging topline data from an early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist having... Read More
category AMLN , ALKS , LLY , and 5 more.
from Stock Blog Hub
Good News For Alkermes Pipeline
February 17, 2010
Recently, Alkermes Inc. (ALKS) announced encouraging topline data from an early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist having... Read More
category AMLN , ALKS , USA , and 5 more.
from DailyMarkets.com
(ALKS) Alkermes Retains Neutral Recommendation
February 08, 2010
We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to... Read More
category AMLN , JNJ , ALKS , and 9 more.
from Stock Blog Hub
Alkermes Retains Neutral Rec « Zacks Investment Research »
February 08, 2010
We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to... Read More
category AMLN , ALKS , External Research , and 6 more.
from DailyMarkets.com
Investors bet against the pharmaceutical concern despite its strong technical uptrend
February 03, 2010
Amylin Pharmaceuticals Inc. (AMLN: sentiment, chart, options) makes and markets two injectable diabetes drugs, Byetta and Symlin, that are approved as adjunct diabetes therapies, according to... Read More
category AMLN
from SchaeffersResearch.com Market Observations
(AMLN) Amylin Pharmaceuticals Misses Earnings Estimates
January 30, 2010
Amylin Pharmaceuticals (AMLN) reported a net loss of 32 cents per share in the fourth quarter of 2009, five cents wider than the Zacks Consensus Estimate of 27 cents. The company had reported a net... Read More
category AMLN , Eli Lilly & Company , Amylin Pharmaceuticals Inc , and 3 more.
from Stock Blog Hub
Amylin Misses Estimates
January 29, 2010
Amylin Pharmaceuticals (AMLN) reported a net loss of 32 cents per share in the fourth quarter of 2009, five cents wider than the Zacks Consensus Estimate of 27 cents. The company had reported a net... Read More
category AMLN , USA , Stocks , and 4 more.
from DailyMarkets.com
Toyota News (NYSE: TM) - Sell Shares Here? - 01-28-10
January 28, 2010
from Wall Street Greek
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here